Skip to main content

Advertisement

Table 1 Baseline characteristics of MSU crystal exposed and propensity score matched unexposed individuals

From: Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study

  MSU crystals No crystals
All 317 (100.0) 317 (100.0)
Male 277 (87.4) 275 (86.8)
Female 40 (12.6) 42 (13.2)
Age 61 (50–74) 62 (50–74)
History of   
 Ischemic heart disease 77 (24.3) 74 (23.3)
 Heart failure 48 (15.1) 45 (14.2)
 Atrial fibrillation 54 (17.0) 54 (17.0)
 Stroke 38 (12.0) 34 (10.7)
 Diabetes mellitus 48 (15.1) 40 (12.6)
 Hypertension 109 (34.4) 100 (31.5)
 COPD 33 (10.4) 30 (9.5)
Charlson comorbidity index   
 0 147 (46.4) 152 (47.9)
 1 62 (19.6) 62 (19.6)
 2 39 (12.3) 41 (12.9)
 ≥3 69 (21.8) 62 (19.6)
Current drug use (baseline)   
 Urate-lowering drugs 49 (15.5) 46 (14.5)
 Diabetes drugs (ever use) 41 (12.9) 33 (10.4)
 Vitamin K antagonists 36 (11.4) 34 (10.7)
 ADP-receptor inhibitor 8 (2.5) 6 (1.9)
 Low-dose ASA 64 (20.2) 56 (17.7)
 Dipyridamole 11 (3.5) 11 (3.5)
 Digitalis 28 (8.8) 29 (9.1)
 Nitrates 15 (4.7) 15 (4.7)
 Thiazide diuretics 27 (8.5) 28 (8.8)
 Loop diuretics 86 (27.1) 85 (26.8)
 Aldosterone antagonists 15 (4.7) 14 (4.4)
 Beta blockers 61 (19.2) 60 (18.9)
 Calcium antagonists 45 (14.2) 46 (14.5)
 RAS blockers 104 (32.8) 101 (31.9)
 Statins 64 (20.2) 56 (17.7)
 COPD drugs 33 (10.4) 32 (10.1)
 Systemic corticosteroids 56 (17.7) 56 (17.7)
 NSAIDs 166 (52.4) 161 (50.8)
Blood measurements (baseline)   
 Urate level 0.53 (0.46–0.61) 0.43 (0.38–0.50)
 Urate level <0.30 mmol/l 0 (0.0) 0 (0.0)
 Urate level 0.30–0.36 mmol/l 7 (2.2) 28 (8.8)
 Urate level 0.37–0.42 mmol/l 43 (13.6) 129 (40.7)
 Urate level 0.43–0.48 mmol/l 72 (22.7) 65 (20.5)
 Urate level >0.48 mmol/l 195 (61.5) 95 (30.0)
 eGFR 68 (51–83) 70 (53–81)
 High HbA1c (>6.5 %) 36 (11.4) 26 (8.2)
 High total cholesterol (>5 mmol/l) 64 (20.2) 67 (21.1)
 Proteinuria 43 (13.6) 38 (12.0)
  1. Data presented as n (%) or median (IQR)
  2. ADP adenosine diphosphate, ASA acetyl salicylic acid, COPD chronic obstructive pulmonary disease, eGFR estimated glomerular filtration rate, HbA1c hemoglobin A1c, IQR interquartile range, MSU monosodium urate, NSAID nonsteroidal anti-inflammatory drug, RAS renin–angiotensin system